Core Insights - Teradata Corp reported better-than-expected third-quarter financial results, with earnings of 72 cents per share, surpassing the analyst consensus estimate of 54 cents per share [2] - The company also reported quarterly sales of $416 million, exceeding the analyst consensus estimate of $406.228 million [2] - Following the positive results, Teradata shares rose 14.6% to $23.73 in pre-market trading [2] - Additionally, Teradata raised its FY25 EPS guidance above estimates and issued fourth-quarter EPS guidance above estimates [1] Financial Performance - Teradata's quarterly earnings were 72 cents per share, beating the expected 54 cents per share [2] - Quarterly sales reached $416 million, surpassing the forecast of $406.228 million [2] Market Reaction - Teradata shares experienced a significant increase of 14.6%, reaching $23.73 in pre-market trading following the earnings report [2]

Core Insights - U.S. stock futures are down, with Dow futures dropping over 300 points [1] - Insperity Inc reported disappointing third-quarter results, leading to a significant drop in its stock price [1][2] Company Performance - Insperity reported a quarterly loss of $0.20 per share, missing the analyst consensus estimate of $0.22 per share [2] - Quarterly sales for Insperity were $1.623 billion, falling short of the analyst consensus estimate of $1.632 billion [2] - Insperity's shares fell 31.3% to $31.00 in pre-market trading following the earnings report [2] Other Companies Impacted - Sarepta Therapeutics Inc saw a decline of 38.7% to $14.98 after reporting third-quarter results and failing to achieve statistical significance in its ESSENCE study [4] - Jeld-Wen Holding Inc's shares dropped 28.1% to $3.02 after reporting worse-than-expected third-quarter results and cutting FY25 guidance [4] - Ichor Holdings Ltd experienced a 26.2% decline to $16.77 after mixed third-quarter results and below-estimate fourth-quarter guidance [4] - Atlas Energy Solutions Inc's shares dipped 17.8% to $10.40 after reporting disappointing third-quarter results [4] - Navitas Semiconductor Corp fell 15.7% to $10.32 following its third-quarter results [4] - Uniqure NV's shares decreased 11.6% to $30.30 after a significant drop of 49% on Monday due to FDA concerns regarding its AMT-130 data [4] - Other companies like Ardelyx Inc, Genius Sports Limited, IAC Inc, and Archer-Daniels-Midland Company also reported declines in pre-market trading due to worse-than-expected financial results or lowered guidance [4]

Core Insights - U.S. stock futures are down, with Dow futures dropping over 300 points [1] - Insperity Inc reported disappointing third-quarter results, leading to a significant drop in its stock price [1][2] Company Performance - Insperity reported a quarterly loss of $0.20 per share, missing the analyst consensus estimate of $0.22 per share [2] - Quarterly sales for Insperity were $1.623 billion, falling short of the analyst consensus estimate of $1.632 billion [2] - Insperity's shares fell 31.3% to $31.00 in pre-market trading following the earnings report [2] Other Companies Impacted - Sarepta Therapeutics Inc saw a 38.7% drop to $14.98 after reporting third-quarter results and failing to achieve statistical significance in its ESSENCE study [4] - Jeld-Wen Holding Inc's shares fell 28.1% to $3.02 after reporting worse-than-expected third-quarter results and cutting FY25 guidance [4] - Ichor Holdings Ltd's shares dipped 26.2% to $16.77 after mixed third-quarter results and below-estimate fourth-quarter guidance [4] - Atlas Energy Solutions Inc's shares decreased by 17.8% to $10.40 after disappointing third-quarter results [4] - Navitas Semiconductor Corp fell 15.7% to $10.32 following its third-quarter results [4] - Uniqure NV's shares dipped 11.6% to $30.30 after a significant drop of 49% on Monday due to FDA concerns regarding its AMT-130 data [4] - Other companies like Ardelyx Inc, Genius Sports Limited, IAC Inc, and Archer-Daniels-Midland Company also experienced declines in pre-market trading due to poor financial results or lowered guidance [4]

Core Insights - Upwork Inc reported better-than-expected third-quarter financial results, with earnings of 36 cents per share, surpassing the Street estimate of 29 cents per share [1] - The company's quarterly revenue reached $201.73 million, exceeding the analyst consensus estimate of $193.34 million [1] - Upwork raised its fourth-quarter guidance above estimates and also increased its FY25 guidance [1] Stock Performance - Upwork shares surged 22.2% to $19.10 in pre-market trading following the positive financial results [2] - Other notable stock movements included PTL Ltd gaining 67.4%, MSP Recovery Inc rising 56.9%, and Denny's Corp increasing by 49.2% due to acquisition news [5] - Conversely, Sarepta Therapeutics Inc saw a significant decline of 38.7% after reporting disappointing third-quarter results [5]

Market Overview - U.S. stocks showed mixed performance, with the Dow Jones index falling by 0.41% to 47,369.42, while the NASDAQ rose by 0.54% to 23,853.68 and the S&P 500 gained 0.22% to 6,855.42 [1] - Consumer discretionary shares increased by 1.8%, while materials stocks decreased by 0.6% [1] Economic Indicators - The ISM manufacturing PMI fell to 48.7 in October from 49.1 in September, below market expectations of 49.5 [2][11] - The S&P Global manufacturing PMI rose to 52.5 in October from 52.0 in September, surpassing the preliminary reading of 52.2 [11] Commodity Prices - Oil prices decreased by 0.1% to $60.93, while gold prices increased by 0.4% to $4,011.80 [5] - Silver prices fell by 0.5% to $47.905, and copper prices dropped by 0.9% to $5.0420 [5] European Market Performance - European shares were mixed, with the eurozone's STOXX 600 gaining 0.07% and Spain's IBEX 35 Index rising 0.03% [6] - London's FTSE 100 fell by 0.16%, Germany's DAX 40 increased by 0.73%, and France's CAC 40 decreased by 0.14% [6] Asian Market Performance - Asian markets closed higher, with Hong Kong's Hang Seng gaining 0.97%, China's Shanghai Composite rising by 0.55%, and India's BSE Sensex increasing by 0.05% [7] Company News - Cipher Mining Inc. shares surged by 22% to $22.82 following a $5.5 billion, 15-year lease agreement with Amazon Web Services for AI workloads [9] - Resolute Holdings Management, Inc. saw an 88% increase in shares to $138.76 after reporting quarterly financial results [9] - Tharimmune, Inc. shares rose by 14% to $3.35 after entering a $540 million private placement for blockchain strategy [9] - uniQure N.V. shares dropped by 50% to $33.64 after receiving FDA feedback on its investigational gene therapy [9] - Alvotech shares fell by 33% to $5.13 following a complete response letter from the FDA regarding its biosimilar candidate [9] - ALPS Group Inc shares decreased by 50% to $1.29 after announcing the pricing of a public offering [9]

Core Insights - uniQure N.V. (NASDAQ:QURE) has been recognized as one of the 12 best-performing stocks over the last three months, with analysts raising price targets following positive trial results for its gene therapy AMT-130 [1][2] Group 1: Analyst Ratings and Price Targets - RBC Capital reiterated a Buy rating on uniQure N.V. and increased its price target from $55 to $65 [1] - H.C. Wainwright raised its price target from $70 to $110 while maintaining a Buy rating [2] Group 2: Clinical Trial Results - The company reported positive topline data from its Phase I/II study of AMT-130 for Huntington's disease, indicating that the therapy slowed disease progression [2][3] - The pivotal study met its primary endpoint, showing that a high dose of AMT-130 slowed the disease by 75% over 36 months, with the treatment being generally safe and well-tolerated [3] Group 3: Regulatory Designations and Future Plans - AMT-130 has received Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT) status from the FDA [3] - uniQure N.V. plans to submit a biologics license application (BLA) in the first quarter of 2026 and aims to launch the treatment in the US later that year [3]

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining 1% on Monday [1] - The Dow increased by 0.04% to 47,583.87, while the S&P 500 rose by 0.48% to 6,872.88 [1] Sector Performance - Consumer discretionary shares increased by 1.8% on Monday [1] - Utilities stocks fell by 0.8% during the same trading session [1] Company Earnings - ON Semiconductor Corporation reported quarterly earnings of 63 cents per share, exceeding the analyst consensus estimate of 59 cents per share [2] - The company also reported quarterly sales of $1.551 billion, surpassing the analyst consensus estimate of $1.515 billion [2] Commodity Prices - Oil prices rose by 0.2% to $61.02, while gold increased by 0.8% to $4,026.60 [4] - Silver traded up 0.6% to $48.47, and copper rose by 0.4% to $5.1090 [4] European Market Performance - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.2% [5] - Spain's IBEX 35 Index rose by 0.2%, while London's FTSE 100 increased by 0.1% [5] - Germany's DAX 40 gained 0.8%, and France's CAC 40 fell by 0.2% [5] Asian Market Performance - Asian markets closed higher, with Hong Kong's Hang Seng gaining 0.97% [6] - China's Shanghai Composite rose by 0.55%, and India's BSE Sensex increased by 0.05% [6] Notable Stock Movements - MSP Recovery, Inc. shares surged 255% to $0.78 [9] - Resolute Holdings Management, Inc. shares increased by 90% to $140.76 after reporting quarterly financial results [9] - Tharimmune, Inc. shares rose by 88% to $5.57 following a $540 million private placement announcement [9] - uniQure N.V. shares dropped 59% to $27.66 after receiving FDA feedback regarding AMT-130 [9] - NOMADAR Corp. shares fell by 52% to $9.98, and ALPS Group Inc shares decreased by 40% to $1.5350 due to public offering pricing [9]

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining 1% on Monday, while the Dow rose 0.04% to 47,583.87 and the S&P 500 increased by 0.48% to 6,872.88 [1] - Consumer discretionary shares jumped by 1.8%, while utilities stocks fell by 0.8% [1] Company Earnings - ON Semiconductor Corporation reported better-than-expected earnings for Q3, posting earnings of 63 cents per share, surpassing the analyst consensus estimate of 59 cents per share [2] - The company also reported quarterly sales of $1.551 billion, exceeding the analyst consensus estimate of $1.515 billion [2] Commodity Market - Oil traded up 0.2% to $61.02, gold rose by 0.8% to $4,026.60, silver increased by 0.6% to $48.47, and copper rose by 0.4% to $5.1090 [4] European Market Performance - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.2%, Spain's IBEX 35 Index rising 0.2%, and London's FTSE 100 increasing by 0.1% [5] Asian Market Performance - Asian markets closed higher, with Hong Kong's Hang Seng gaining 0.97%, China's Shanghai Composite rising 0.55%, and India's BSE Sensex increasing by 0.05% [6] Notable Stock Movements - MSP Recovery, Inc. shares surged 255% to $0.78, while Resolute Holdings Management, Inc. shares rose 90% to $140.76 after reporting quarterly financial results [9] - Tharimmune, Inc. shares increased by 88% to $5.57 following a $540 million private placement [9] - uniQure N.V. shares dropped 59% to $27.66 after receiving FDA feedback regarding its investigational gene therapy [9] - NOMADAR Corp. shares fell 52% to $9.98, and ALPS Group Inc shares decreased by 40% to $1.5350 due to public offering pricing announcement [9]

Group 1: Market Overview - U.S. stock futures showed mixed results, with Nasdaq futures gaining over 100 points [1] Group 2: Kimberly-Clark Corporation - Kimberly-Clark Corporation announced the acquisition of Kenvue in a cash and stock transaction valued at approximately $48.7 billion [1] - Following the announcement, Kimberly-Clark shares fell sharply by 13.6% to $103.50 in pre-market trading [1] Group 3: Other Notable Stock Movements - uniQure N.V. shares dropped 65.3% to $23.40 after receiving FDA feedback regarding its investigational gene therapy AMT-130 [3] - ClearPoint Neuro, Inc. saw a decline of 40.5% to $13.77 in pre-market trading [3] - ALPS Group Inc fell 40.2% to $1.53 following the announcement of a public offering [3] - Biohaven Ltd. shares decreased by 27.4% to $12.48 [3] - Alvotech experienced a 24.1% drop to $5.80 after receiving an FDA Complete Response Letter for its AVT05 biosimilar application [3] - Replimune Group, Inc. dipped 16.7% to $8.10, despite an upgrade from BMO Capital [3] - Praxis Precision Medicines, Inc. declined 9.1% to $180.70 [3] - Vertex, Inc. fell 6.1% to $21.50 after lowering its FY2025 sales guidance [3]

Group 1 - U.S. stock futures showed mixed results, with Nasdaq futures gaining over 100 points [1] - Kimberly-Clark Corporation announced the acquisition of Kenvue for approximately $48.7 billion, leading to a 13.6% drop in its shares to $103.50 in pre-market trading [1] Group 2 - uniQure N.V. experienced a significant decline of 65.3% to $23.40 after receiving FDA feedback regarding its investigational gene therapy AMT-130 [3] - ClearPoint Neuro, Inc. shares fell 40.5% to $13.77, while ALPS Group Inc dropped 40.2% to $1.53 following the announcement of a public offering [3] - Biohaven Ltd. shares decreased by 27.4% to $12.48, and Alvotech fell 24.1% to $5.80 after receiving an FDA Complete Response Letter [3] - Replimune Group, Inc. saw a 16.7% dip to $8.10, despite an upgrade from BMO Capital analyst [3] - Praxis Precision Medicines, Inc. declined 9.1% to $180.70, and Vertex, Inc. fell 6.1% to $21.50 after lowering its FY2025 sales guidance [3]